Acute vs. Acute-on-Chronic Liver Failure: Clinical Outcomes
Okay, here’s a breakdown of the key points from the provided text regarding neutrophil-to-lymphocyte ratio (NLR) and immune dysfunction in liver failure (LF) and acute-on-chronic liver failure (ACLF):
1. NLR and Mortality in Acute Liver Failure (ALF):
The study found that NLR did not substantially affect 90-day mortality in ALF patients.
This lack of correlation is potentially explained by complexities in immune responses.
2. Neutrophil and Lymphocyte Counts in Disease:
Neutrophils: Typically increase during inflammation, but this increase may not occur in conditions like cachexia.
Lymphocytes: Decrease as inflammation progresses, but this decrease is frequently enough delayed and may not accurately reflect the stage of the disease.
3. Immune dysfunction in Liver Failure (LF) & Acute-on-Chronic Liver Failure (ACLF):
LF is characterized by a dynamic, multisystem process with defects in both cellular and soluble components of the immune system.
This leads to acquired immunodeficiency, impairing the body’s ability to fight off infections.
Immune dysfunction is central to the growth of LF and is believed to contribute to infectious complications and reduced patient survival.
ACLF patients have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK.
In essence,the text suggests that while NLR is a commonly used marker of inflammation,it may not be a reliable predictor of outcome in ALF due to the complex and frequently enough atypical immune responses seen in liver diseases. The immune dysfunction itself is a key factor driving the severity and prognosis of LF and ACLF.